Study findings may enhance corneal allograft survival

Article

A new study from The American Society of Transplantation and The American Society of Transplant Surgeons suggests HC-matching, in combination with blockade of IFN-y, holds promise as a means of enhancing corneal allograft survival.

A new study from The American Society of Transplantation and The American Society of Transplant Surgeons suggests HC-matching, in combination with blockade of IFN-y, holds promise as a means of enhancing corneal allograft survival. Th1 CD4+ cells are believed to be the primary mediators of corneal allograft rejection. However, rejection of fully allogeneic C57BL/6 corneal allografts soared from 50% to 90% in both interferon-gamma (IFN-γ)(-/-) and anti-IFN-γ-treated BALB/c mice. In contrast, similar deficits in IFN-γ in BALB/c hosts enhanced immune privilege of BALB.B (minor histocompatibility [minor H] antigen-matched, major histocompatibility complex [MHC]-mismatched) and NZB (MHC-matched, minor H antigen-mismatched) corneal allografts-decreasing rejection from 80% to ~20%.

This effect of IFN-γ was independent of CD4+ T cell lineage commitment as both anti-IFN-γ-treated acceptor and rejector mice displayed a Th2 cytokine profile. The presence of IFN-γ prevented the generation of alloantigen-specific CD4+CD25+ T regulatory cells (Tregs) in hosts receiving either MHC only mismatched BALB.B or minor only histocompatibility (minor H)-mismatched NZB corneal allografts. Tregs in these hosts promoted corneal allograft survival by suppressing Th2 effector cells. By contrast, IFN-γ was necessary for the generation of CD4+CD25+ Tregs that prevented rejection of fully allogeneic C57BL/6 corneal allografts in BALB/c hosts.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Jade Coats, OD, FAAO, gives her insight on what makes EyeCon valuable for eye care providers.
Allen, OD, FAAO, Dipl ABO, plans to talk all things ocular surface for optometrists and ophthalmologists alike.
Another drop in the presbyopia bucket: Dr Bloomenstein shares his excitement for the FDA approval of Vizz
© 2025 MJH Life Sciences

All rights reserved.